Healthcare Industry News: Stentys
News Release - March 17, 2011
STENTYS Expands Operations into Four Additional European CountriesPRINCETON, N.J. & PARIS--(Healthcare Sales & Marketing Network)-- Stentys S.A. (STNT.PA), a medical technology company that is commercializing a new generation of innovative stents to treat acute myocardial infarction (AMI), announced today the launch of the Stentys stents in four additional European countries: Scandinavia, Spain, Switzerland and Poland.
Stentys reported 66.7% increase in revenue for the fourth quarter of 2010, compared to the third quarter of 2010. The boost in sales was due in large part to increased physician acceptance in Germany and the Netherlands. The availability of the Stentys stents in four additional countries should contribute to Group revenues starting in the second half of the current financial year.
Stentys 2010 financial statements will be published on 24 March 2011.
Based in Princeton, N.J., and Paris, Stentys has developed a new generation of stents to treat acute myocardial infarction (AMI). Founded by Jacques Séguin, M.D., Ph.D., (also founder of CoreValve, which was acquired by Medtronic) and Gonzague Issenmann, Stentys received CE-marking for its flagship products in 2010. Its self-apposing stent adapts to the anatomic changes of arteries in the post-infarction phase and thus prevent the malapposition problem associated with conventional stents. Stentys has commenced marketing activities in several European countries.
This announcement is not an offer for sale of securities in the United States. The securities referred to herein have not been offered or sold in the United States and may not be offered or sold in the United States of America, except pursuant to a registration statement under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or pursuant to an exemption from registrations thereunder. This press release is being issued pursuant to and in accordance with Rule 135c under the Securities Act.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.